Skip to content
Screener

Syndax Pharmaceuticals SNDX D&A

D&A at other companies

Biogen logo
BiogenBIIB
$236.1M+21.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$316K-80.4%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$172.3M+11.6%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.82B+68.8%
Enterprise value$2.04B+56.8%
P/S8.4×-5.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154

Depreciation expense was $4,000 for the three months ended March 31, 2026. There was no depreciation expense for the three months ended March 31, 2025.

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's D&A?
Syndax Pharmaceuticals (SNDX) reported D&A of $4M in Q1 2026.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Syndax Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude